

Ref. No.: EIKO/BSE/2024-25/45

Date: 05th November, 2024

To,
Corporate Services Department **BSE Limited**Phiroze Jeejeebhoy Towers,
1st Floor, Dalal Street,
Fort, Mumbai – 400001

Scrip Code: 540204

<u>Subject: Intimation under Regulation 30 of the SEBI (LODR) Regulations 2015 and Press Release</u>

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015 and all the other applicable provisions thereto, please find attached the press release relating to Diversification of Business.

Kindly take the above on record and oblige.

For Eiko LifeSciences Limited

Chintan Doshi
Company Secretary and Compliance Officer

Membership No: ACS 36190

Encl. As Above



Press Release

Eiko LifeSciences Limited (BSE: 540204) is pleased to announce its strategic diversification into the comprehensive shipping, logistics, and container management solutions across multiple industries, including but not limited to hazardous and non-hazardous chemicals, aimed at enhancing backward and forward integration and mitigating inherent business risks.

The company plans to:

- 1. Diversify into leasing, renting, and managing shipping containers for logistics, storage, and transportation of goods.
- 2. Source containers domestically and internationally.
- 3. Offer leasing services to entities involved in goods transport.
- 4. Provide maintenance and management services for efficient container operations and other logistics services.

This strategic expansion will enable Eiko LifeSciences Limited to:

- Enhance its supply chain efficiency
- Diversify revenue streams
- Leverage growth opportunities in the logistics sector

EikoVivify Logistics Private Limited (EVL), a strategic subsidiary of Eiko Lifesciences Limited, has been established with a joint investment structure. Eiko Lifesciences Limited holds a 51% stake, while M/s Vivify Wealth Management LLP holds the remaining 49%.

The joint venture partners have committed to investing ₹100 crores over a three-year period. This investment will be utilized to drive growth and expansion.

As part of its growth strategy, EVL is actively pursuing the discussion with operational joint venture partners to enhance its service offerings. The company anticipates generating revenue from this venture starting from the last quarter of FY 2024-25.

Registered Address: 604, Centrum, Opp. TMC Office, Near Satkar Grande Hotel, Wagle Estate, Thane MH 400604 Phone No.: +919082668855; Email id: investor.relations@eikolifesciences.com website: www.eikolifesciences.com